BAC
Bank of America Corporation
BAC has lower modeled downside risk, despite its lower overall score.
HLNE
Hamilton Lane Incorporated
HLNE has the edge over BAC overall, supported by stronger fundamentals.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
HLNE Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| N/A | |
| N/A |
HLNE's revenue and profitability are currently strong. Free cash flow and net leverage aren't meaningful measures for financial services companies like HLNE.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
HLNE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $93.88 | — |
| Current | 14x | $93.88 | — |
| Cheap | 17x | $116 | +24% |
| Fair | 27x | $179 | +91% |
| Expensive | 37x | $249 | +165% |
Historical ranges are pointers, not guarantees.
HLNE has the edge over BAC in the historical PE scenario, which offers more potential upside but is not a forecast.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
HLNE Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for HLNE, with profitability improving.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
HLNE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.30 | +8.4% |
| Q3 2026 | $6.74 | +22% |
| Q2 2026 | $6.56 | +26% |
| Q1 2026 | $5.91 | +9.6% |
| Q4 2025 | $5.57 | +1.6% |
| Q4 2021 | $4.59 | +89% |
| Q3 2021 | $4.15 | +115% |
| Q2 2021 | $3.40 | +86% |
| Q1 2021 | $2.73 | +28% |
HLNE has the edge over BAC on earnings, with stronger typical year-over-year growth.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
HLNE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $204.4M | +7.1% |
| Q2 2026 | $275.3M | +56% |
| Q1 2026 | $193.6M | -2.2% |
| Q4 2025 | $198.6M | +18% |
| Q3 2025 | $190.9M | +27% |
| Q2 2025 | $176M | -11% |
| Q1 2025 | $198M | +18% |
| Q2 2024 | $196.7M | +57% |
HLNE's revenue is growing: $204M last quarter, up 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 87% | +46 points |
| Q2 2026 | 46% | +2.2 points |
| Q1 2026 | 42% | 0 points |
| Q4 2025 | 43% | -1.7 points |
| Q3 2025 | 42% | -3 points |
| Q2 2025 | 44% | -1.8 points |
| Q1 2025 | 42% | -2.5 points |
| Q4 2024 | 45% | N/A |
HLNE has the edge over BAC on profitability, with a higher operating margin.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
HLNE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $22.8M | -81% |
| Q2 2026 | $98.9M | -22% |
| Q1 2026 | $101.2M | +182% |
| Q4 2025 | $72.4M | +23% |
| Q3 2025 | $120.1M | +3.7% |
| Q2 2025 | $127.6M | +63% |
| Q1 2025 | $35.8M | +78% |
| Q2 2024 | $78.2M | 0% |
HLNE has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over HLNE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
HLNE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.5% | +1.3M shares |
| 1 year | +2.3% | +1.3M shares |
| 3 years | +3.8% | +2M shares |
| 5 years | +60% | +21M shares |
| Available history | +88% | +26.1M shares |
HLNE has 56M diluted shares, up 2.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $50.6M |
| Q1 2026 | $23.2M |
| Q4 2025 | $595,000 |
| Q3 2025 | $835,000 |
| Q2 2025 | $7,000 |
| Q1 2025 | $252.9M |
| Q4 2024 | $72,000 |
| Q3 2024 | $391,000 |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
HLNE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | 0.2x | Very low |
| Q4 2024 | 0.1x | Very low |
HLNE has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
HLNE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 31.1 | Neutral |
HLNE's weekly RSI is 51 (neutral) and its Stochastic is 31 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over HLNE on valuation relative to its sector.
HLNE PE vs Financial Services Sector
| Metric | HLNE | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 7% above |
| PE % | 4 | 63 | 59 pts below |
HLNE is trading at 14x earnings, in line with the Financial Services sector's median of 13x, though its earnings don't support one.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
HLNE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $86.3 | 8.8% above |
| 20 week MA | $90.6 | 3.6% above |
| 50 week MA | $101.7 | 7.7% below |
| 100 week MA | $123.8 | 24% below |
| 200 week MA | $117.2 | 20% below |
HLNE has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has the edge over HLNE on returns for 2026, with the stronger performance.
HLNE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $61.2 | $78.7 | +29% |
| 2021 | $78.7 | $103.7 | +32% |
| 2022 | $103.7 | $65.5 | -37% |
| 2023 | $65.5 | $113.4 | +73% |
| 2024 | $113.4 | $151.6 | +34% |
| 2025 | $151.6 | $138.5 | -8.6% |
| 2026 YTD | $138.5 | $93.9 | -32% |
HLNE is down 32% so far in 2026, after finishing higher in four of the previous six years.